Shu Liu

Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells

Bin You, Yi‐Lin Yang, Zhidong Xu et al. · Oncotarget · 2015 · 102 citations · Full text

Life Sciences, Cancer Biology, Cell Biology +17

Design, synthesis and pharmacological evaluation of novel tacrine–caffeic acid hybrids as multi-targeted compounds against Alzheimer’s disease

Xiaojuan Chao, Xixin He, Yilin Yang et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 101 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

Linong Ji, Yanmei Liu, Heng Miao et al. · Diabetes Obesity and Metabolism · 2019 · 52 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The crystal structure of the protein kinase HIPK2 reveals a unique architecture of its CMGC-insert region

Christopher Agnew, Lijun Liu, Shu Liu et al. · Journal of Biological Chemistry · 2019 · 33 citations · Full text

Life Sciences, Molecular Biology, Oncology +13

Ajmalicine and its Analogues Against AChE and BuChE for the Management of Alzheimer’s Disease: An In-silico Study

Shu Liu, Minyan Dang, Yan Lei et al. · Current Pharmaceutical Design · 2020 · 13 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17